The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomas

Marko M. Altaras, Gary L. Goldberg, Wilfred Levin, Basil Bloch, Lynne Darge, James A. Smith

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

From June 1, 1984, to May 31, 1985, 98 cases of epithelial ovarian carcinomas were assessed and followed prospectively using a new murine monoclonal antibody OC 125 which detects the antigen CA 125. Serous tumors comprised 43.7% of cases, mucinous tumors 20.4%, endometrioid tumors 16%, and other epithelial tumors 19.4%. Tumors of low malignant potential and benign epithelial cystadenomas were not included. For this study the upper limit of normal for CA 125 was 20 U/ml. Thirty-six were new cases. In this group the initial CA 125 levels >20 U/ml, >35 U/ml, and >65 U/ml were 97.2, 94.4, and 86.1%, respectively. When mucinous types were excluded the specificity rate did not change significantly. There was no significant difference in initial CA 125 levels between early stages I and II and late stages III and IV. No correlation between tumor bulk and the serum level of antigen was observed. The remaining 62 patients were being followed and in this group 50 were considered to be in remission. Six cases in the remission group had elevated CA 125 levels >20 U/ml and 5 of these developed clinical recurrence. The correlation between the clinical status and concordant fluctuations in the serum levels of CA 125 in all histological types was 87.8 and 93.5% when 10 cases of mucinous tumors were excluded. The contingency coefficient was 0.746. Seven SLOs were performed. All had CA 125 levels <20 U/ml and the mean was 6.9 U/ml. Only 1 case was positive with microscopic disease. In our experience CA 125 was invaluable in the management and follow-up of patients with ovarian carcinoma especially for the early detection of recurrent disease and for the monitoring of patients on therapy.

Original languageEnglish (US)
Pages (from-to)26-34
Number of pages9
JournalGynecologic Oncology
Volume30
Issue number1
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Carcinoma
Antigens
Neoplasms
Cystadenoma
Physiologic Monitoring
Serum
Early Diagnosis
Monoclonal Antibodies
Recurrence

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Altaras, M. M., Goldberg, G. L., Levin, W., Bloch, B., Darge, L., & Smith, J. A. (1988). The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomas. Gynecologic Oncology, 30(1), 26-34. https://doi.org/10.1016/0090-8258(88)90042-X

The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomas. / Altaras, Marko M.; Goldberg, Gary L.; Levin, Wilfred; Bloch, Basil; Darge, Lynne; Smith, James A.

In: Gynecologic Oncology, Vol. 30, No. 1, 1988, p. 26-34.

Research output: Contribution to journalArticle

Altaras, MM, Goldberg, GL, Levin, W, Bloch, B, Darge, L & Smith, JA 1988, 'The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomas', Gynecologic Oncology, vol. 30, no. 1, pp. 26-34. https://doi.org/10.1016/0090-8258(88)90042-X
Altaras, Marko M. ; Goldberg, Gary L. ; Levin, Wilfred ; Bloch, Basil ; Darge, Lynne ; Smith, James A. / The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomas. In: Gynecologic Oncology. 1988 ; Vol. 30, No. 1. pp. 26-34.
@article{274b16c074f049c98e43c93d93ba4b86,
title = "The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomas",
abstract = "From June 1, 1984, to May 31, 1985, 98 cases of epithelial ovarian carcinomas were assessed and followed prospectively using a new murine monoclonal antibody OC 125 which detects the antigen CA 125. Serous tumors comprised 43.7{\%} of cases, mucinous tumors 20.4{\%}, endometrioid tumors 16{\%}, and other epithelial tumors 19.4{\%}. Tumors of low malignant potential and benign epithelial cystadenomas were not included. For this study the upper limit of normal for CA 125 was 20 U/ml. Thirty-six were new cases. In this group the initial CA 125 levels >20 U/ml, >35 U/ml, and >65 U/ml were 97.2, 94.4, and 86.1{\%}, respectively. When mucinous types were excluded the specificity rate did not change significantly. There was no significant difference in initial CA 125 levels between early stages I and II and late stages III and IV. No correlation between tumor bulk and the serum level of antigen was observed. The remaining 62 patients were being followed and in this group 50 were considered to be in remission. Six cases in the remission group had elevated CA 125 levels >20 U/ml and 5 of these developed clinical recurrence. The correlation between the clinical status and concordant fluctuations in the serum levels of CA 125 in all histological types was 87.8 and 93.5{\%} when 10 cases of mucinous tumors were excluded. The contingency coefficient was 0.746. Seven SLOs were performed. All had CA 125 levels <20 U/ml and the mean was 6.9 U/ml. Only 1 case was positive with microscopic disease. In our experience CA 125 was invaluable in the management and follow-up of patients with ovarian carcinoma especially for the early detection of recurrent disease and for the monitoring of patients on therapy.",
author = "Altaras, {Marko M.} and Goldberg, {Gary L.} and Wilfred Levin and Basil Bloch and Lynne Darge and Smith, {James A.}",
year = "1988",
doi = "10.1016/0090-8258(88)90042-X",
language = "English (US)",
volume = "30",
pages = "26--34",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomas

AU - Altaras, Marko M.

AU - Goldberg, Gary L.

AU - Levin, Wilfred

AU - Bloch, Basil

AU - Darge, Lynne

AU - Smith, James A.

PY - 1988

Y1 - 1988

N2 - From June 1, 1984, to May 31, 1985, 98 cases of epithelial ovarian carcinomas were assessed and followed prospectively using a new murine monoclonal antibody OC 125 which detects the antigen CA 125. Serous tumors comprised 43.7% of cases, mucinous tumors 20.4%, endometrioid tumors 16%, and other epithelial tumors 19.4%. Tumors of low malignant potential and benign epithelial cystadenomas were not included. For this study the upper limit of normal for CA 125 was 20 U/ml. Thirty-six were new cases. In this group the initial CA 125 levels >20 U/ml, >35 U/ml, and >65 U/ml were 97.2, 94.4, and 86.1%, respectively. When mucinous types were excluded the specificity rate did not change significantly. There was no significant difference in initial CA 125 levels between early stages I and II and late stages III and IV. No correlation between tumor bulk and the serum level of antigen was observed. The remaining 62 patients were being followed and in this group 50 were considered to be in remission. Six cases in the remission group had elevated CA 125 levels >20 U/ml and 5 of these developed clinical recurrence. The correlation between the clinical status and concordant fluctuations in the serum levels of CA 125 in all histological types was 87.8 and 93.5% when 10 cases of mucinous tumors were excluded. The contingency coefficient was 0.746. Seven SLOs were performed. All had CA 125 levels <20 U/ml and the mean was 6.9 U/ml. Only 1 case was positive with microscopic disease. In our experience CA 125 was invaluable in the management and follow-up of patients with ovarian carcinoma especially for the early detection of recurrent disease and for the monitoring of patients on therapy.

AB - From June 1, 1984, to May 31, 1985, 98 cases of epithelial ovarian carcinomas were assessed and followed prospectively using a new murine monoclonal antibody OC 125 which detects the antigen CA 125. Serous tumors comprised 43.7% of cases, mucinous tumors 20.4%, endometrioid tumors 16%, and other epithelial tumors 19.4%. Tumors of low malignant potential and benign epithelial cystadenomas were not included. For this study the upper limit of normal for CA 125 was 20 U/ml. Thirty-six were new cases. In this group the initial CA 125 levels >20 U/ml, >35 U/ml, and >65 U/ml were 97.2, 94.4, and 86.1%, respectively. When mucinous types were excluded the specificity rate did not change significantly. There was no significant difference in initial CA 125 levels between early stages I and II and late stages III and IV. No correlation between tumor bulk and the serum level of antigen was observed. The remaining 62 patients were being followed and in this group 50 were considered to be in remission. Six cases in the remission group had elevated CA 125 levels >20 U/ml and 5 of these developed clinical recurrence. The correlation between the clinical status and concordant fluctuations in the serum levels of CA 125 in all histological types was 87.8 and 93.5% when 10 cases of mucinous tumors were excluded. The contingency coefficient was 0.746. Seven SLOs were performed. All had CA 125 levels <20 U/ml and the mean was 6.9 U/ml. Only 1 case was positive with microscopic disease. In our experience CA 125 was invaluable in the management and follow-up of patients with ovarian carcinoma especially for the early detection of recurrent disease and for the monitoring of patients on therapy.

UR - http://www.scopus.com/inward/record.url?scp=0023903222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023903222&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(88)90042-X

DO - 10.1016/0090-8258(88)90042-X

M3 - Article

C2 - 2452770

AN - SCOPUS:0023903222

VL - 30

SP - 26

EP - 34

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -